苏州昊帆生物股份有限公司（以下简称"公司"）第四届监事会第十一次会 议于 2025 年 10 月 27 日在公司以现场方式召开。会议通知于 2025 年 10 月 24 日以专人送达及电话等方式发出。 本次会议由监事会主席孙豪义先生主持，会议应出席监事 3 人，实际出席监 事 3 人。董事会秘书列席本次会议。本次会议的召集、召开符合本次会议的召集、 召开符合《公司法》和《公司章程》的有关规定。 证券代码：301393 证券简称：昊帆生物 公告编号：2025-052 苏州昊帆生物股份有限公司 第四届监事会第十一次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 二、监事会会议审议情况 与会监事以记名投票表决方式，审议并通过了如下议案： （一）审议并通过《关于公司 2025 年第三季度报告的议案》 经审议，监事会认为：董事会编制和审核公司 2025 年第三季度报告的程序 符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了 公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：3 名监事同意， ...

证券代码：301393 证券简称：昊帆生物 公告编号：2025-051 苏州昊帆生物股份有限公司 公司董事会经审议认为：公司 2025 年第三季度报告所载内容真实、准确、 完整，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：9 名董事同意，占全体董事人数的 100%；0 名弃权，0 名反对。 本议案已经公司审计委员会审议通过，并一致同意提交董事会审议。 第四届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 苏州昊帆生物股份有限公司（以下简称"公司"）第四届董事会第十三次会 议于 2025 年 10 月 27 日以通讯方式召开，会议通知于 2025 年 10 月 24 日以专人 送达及电话等方式发出。 本次会议由董事长朱勇先生主持，会议应出席董事 9 人，实际出席 9 人。公 司全体监事、高级管理人员列席本次会议。本次会议的召集、召开符合《公司法》 和《公司章程》的有关规定。 二、董事会会议审议情况 与会董事以记名投票表决方式，审议并通过了如下议案： （一）审议并通过《关于公司 2025 年第三季度报 ...

苏州昊帆生物股份有限公司 关于公司 2025 年中期现金分红方案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：301393 证券简称：昊帆生物 公告编号：2025-053 特别提示： 1、每股分配比例：每 10 股派发现金红利 1.35 元（含税）。 2、本次利润分配以实施权益分派股权登记日登记的总股本扣减公司回购专 用证券账户中的股份为基数，具体日期将在权益分派实施公告中明确。 3、在实施权益分派的股权登记日前苏州昊帆生物股份有限公司总股本发生 变动的，维持分配比例不变，相应调整分配总额，并将另行公告具体调整情况。 4、本次 2025 年中期现金分红事项已经 2024 年度股东大会审议通过，授权 董事会制定并实施具体的现金分红方案。 苏州昊帆生物股份有限公司（以下简称"公司"）于 2025 年 10 月 27 日召 开第四届董事会第十三次会议、第四届监事会第十一次会议，审议通过了《关于 公司 2025 年中期现金分红方案的议案》，该事项已经公司 2024 年度股东大会授 权，无需提交股东大会审议。现将具体情况公告如下： 一、利润分配方案的 ...

Core Viewpoint - Haofan Bio reported a significant increase in revenue for Q3 2025, but a decline in net profit compared to the previous year [1] Financial Performance - In Q3 2025, the company achieved a revenue of 164 million yuan, representing a year-on-year growth of 59.45% [1] - The net profit attributable to shareholders was 23.35 million yuan, showing a decrease of 23.50% year-on-year [1] - Basic earnings per share for Q3 2025 were 0.22 yuan [1] Year-to-Date Performance - For the first three quarters of 2025, the company reported a total revenue of 435 million yuan, which is a year-on-year increase of 32.47% [1] - The net profit attributable to shareholders for the first three quarters was 99.24 million yuan, reflecting a growth of 3.01% year-on-year [1] - Basic earnings per share for the first three quarters were 0.93 yuan [1]

Revenue and Profitability - Revenue for Q3 2025 reached ¥164,399,742.15, an increase of 59.45% year-over-year[5] - Net profit attributable to shareholders decreased by 23.50% to ¥23,353,545.93 in Q3 2025[5] - Net profit excluding non-recurring items was ¥19,271,570.19, down 20.76% compared to the same period last year[5] - The company's operating revenue for the first three quarters of 2025 reached ¥434.70 million, a 32.47% increase compared to ¥328.16 million in the same period of 2024[10] - The net profit for the reporting period, excluding the impact of the newly acquired Foster Pharmaceuticals, was ¥36.76 million, reflecting a 20.43% year-on-year growth[10] - Net profit for the current period was ¥99,238,347.92, representing a 3.0% increase compared to ¥96,335,195.65 in the previous period[29] Assets and Liabilities - Total assets increased by 8.52% to ¥2,549,790,054.85 as of September 30, 2025[5] - The total liabilities increased to CNY 181,886,840.09 from CNY 71,162,838.83, indicating a significant rise of approximately 156.5%[24] - The company reported a total current assets of CNY 1,835,895,685.80 as of September 30, 2025, down from CNY 1,944,260,056.93 at the beginning of the period, representing a decrease of approximately 5.57%[22] - The total non-current assets increased to CNY 713,894,369.05 from CNY 405,359,118.69, showing an increase of approximately 76%[23] Cash Flow - Cash flow from operating activities showed a significant decline of 55.23%, totaling ¥47,723,128.59 year-to-date[5] - Cash inflow from operating activities totaled ¥393,575,655.90, compared to ¥368,404,311.40 in the previous period, reflecting a growth of 6.9%[31] - The net cash flow from operating activities was $47,723,128.59, a decrease of 55.3% compared to $106,599,489.96 in the previous period[32] - The total cash inflow from investment activities was $4,031,521,486.09, significantly up from $739,050,803.89, marking an increase of 445.5%[32] - The net cash flow from investment activities was $354,383,240.84, recovering from a negative cash flow of -$950,298,018.67 in the previous period[32] - The total cash inflow from financing activities was $79,601,100.00, compared to $11,500,000.00 in the previous period, representing an increase of 592.3%[32] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,024, with the largest shareholder holding 47.40% of the shares[13] - The company adjusted the grant price for the 2024 restricted stock incentive plan from CNY 22.30 per share to CNY 21.91 per share due to mid-year equity distribution[17] - The company plans to grant 179,000 shares of the second category of restricted stock to 13 eligible participants at the adjusted price of CNY 21.91 per share on July 2, 2025[17] Acquisitions and Goodwill - The company acquired a subsidiary, resulting in goodwill of ¥71,721,165.16[9] - The company completed the acquisition of 100% equity in Hangzhou Foster Pharmaceutical Co., Ltd., with the first phase of the equity transfer completed on July 9, 2025, resulting in the company holding 85% of the shares[19] - The company acquired Hangzhou Foster Pharmaceuticals in July 2025, which reported an operating revenue of ¥20.93 million and a net loss of ¥13.41 million during the reporting period[10] - The company's goodwill increased to CNY 71,721,165.16, reflecting the impact of recent acquisitions[23] Financial Performance Metrics - The weighted average return on equity decreased to 1.01%, down 0.36 percentage points from the previous year[5] - Basic earnings per share increased to ¥0.93 from ¥0.90, while diluted earnings per share rose to ¥0.92 from ¥0.89[30] - Total operating costs amounted to ¥336,820,135.14, up 47.4% from ¥228,599,500.59 year-over-year[28] - Research and development expenses were ¥30,612,903.47, up from ¥26,225,248.09, indicating a focus on innovation[28] Tax and Financial Charges - The company reported a significant increase in tax and additional charges by 82.77% to ¥4.67 million, primarily due to increased additional taxes[10] - The deferred income tax liabilities increased by 768.82% to ¥8.15 million, mainly due to the recognition of deferred taxes from the newly acquired assets of Foster Pharmaceuticals[10] Financial Adjustments - The financial expenses decreased by 67.06% to -¥8.20 million, attributed to adjustments in cash management product types[10] - The investment income surged by 975.39% to ¥12.61 million, due to changes in cash management product types[10] - The company reported a financial income of ¥12,832,185.57, down from ¥28,050,784.16, suggesting a decrease in interest income[28] Audit Information - The company did not undergo an audit for the third quarter financial report[34]

证券代码：301393 证券简称：昊帆生物 公告编号：2025-049 苏州昊帆生物股份有限公司 关于为全资子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 公司于 2025 年 8 月 27 日召开第四届董事会第十二次会议、第四届监事会第 十次会议，审议通过了《关于为全资子公司提供担保的议案》。为满足项目建设 需要，公司拟为全资子公司淮安昊帆生物医药有限公司（以下简称"淮安昊帆"） 向交通银行股份有限公司申请贷款等融资业务提供不超过人民币 50,000.00 万元 （含本数）的连带责任担保；为满足日常经营需要，公司拟为全资子公司苏州昊 帆进出口有限公司（以下简称"昊帆进出口"）向宁波银行股份有限公司办理授 信业务提供不超过 10,000.00 万元（含本数）的连带责任担保。担保范围、金额、 期限等具体内容以最终签订的相关担保协议为准。董事会授权公司法定代表人或 法定代表人指定的授权代理人代表公司及全资子公司办理相关手续，并在担保额 度范围内与金融机构签署授信及担保相关的合同、协议、凭证等一切法律文件。 具体内容详见公 ...

Core Viewpoint - Haofan Bio, a leader in the domestic peptide synthesis reagent sector, has shown significant growth and is well-positioned to capitalize on the expanding global biopharmaceutical market, particularly in peptide drugs [2][6]. Financial Performance - In the first half of 2025, Haofan Bio reported a revenue of 270 million yuan, representing a year-on-year growth of 20.1%, and a net profit attributable to shareholders of 75.88 million yuan, up 15.3% year-on-year [2]. R&D and Capacity Upgrades - Following its listing on the ChiNext board in 2023, Haofan Bio has accelerated its dual upgrades in R&D and production capacity, with a 30% increase in R&D personnel and the construction of three production bases to alleviate capacity constraints [3][6]. - The company has also established a new R&D building and introduced advanced research and testing equipment [3]. Technology and Product Development - Haofan Bio has developed a comprehensive range of peptide synthesis reagents, from the first to the fourth generation, becoming one of the few global manufacturers to cover the entire series [4][5]. - The company is actively expanding its product system to include general molecular building blocks and pharmaceutical reagents for liposomes and lipid nanoparticles, with over 120 types of these reagents in small-scale research and some entering small batch production [5]. Market Opportunities and Challenges - The global peptide drug market is expected to exceed $100 billion by 2027, presenting significant opportunities for Haofan Bio, although capacity shortages remain a critical issue [6]. - The company plans to address this by acquiring Foster Pharmaceutical for 160 million yuan, which will provide additional production capacity and facilitate the transition of new products from small-scale trials to mass production [6]. Strategic Focus - Haofan Bio emphasizes a strategy of solidifying its core product quality and maintaining market position while providing comprehensive support to clients throughout their development stages [7]. - The company aims to avoid blind pursuit of trends and instead focus on steady innovation to serve the global market effectively [7].

Core Insights - The article highlights the growth and strategic direction of Haofan Bio, a leader in the peptide synthesis reagent sector, emphasizing its commitment to innovation and market stability in the global biopharmaceutical landscape [2][3][4]. Financial Performance - In the first half of 2025, Haofan Bio reported a revenue of 270 million yuan, representing a year-on-year increase of 20.1%, and a net profit attributable to shareholders of 75.88 million yuan, up 15.3% year-on-year [2]. Market Position and Strategy - Haofan Bio has been deeply engaged in the peptide synthesis reagent market for over 20 years, successfully developing first to fourth generation reagents, which positions the company as one of the few global manufacturers covering the entire series [2][4]. - The company aims to build a technological "moat" in the peptide sector, focusing on high-quality products and maintaining its market position through steady innovation [2][4]. R&D and Capacity Expansion - Following its listing on the ChiNext board in 2023, Haofan Bio has accelerated its R&D and production capacity upgrades, including the construction of a new R&D building and the introduction of advanced equipment, increasing its R&D personnel by 30% [3][6]. - The company is also expanding its production bases to alleviate capacity constraints, with plans to establish 3 to 5 workshops at its Huai'an production base by next year [6]. Acquisition Strategy - A key part of Haofan Bio's strategy to address capacity issues includes the planned acquisition of Hangzhou Foster Pharmaceutical for 160 million yuan, which will provide additional production capacity and facilitate the transition of new products from small-scale to larger-scale production [6][7]. Future Outlook - The global peptide drug market is expected to exceed 100 billion USD by 2027, presenting significant growth opportunities for Haofan Bio, although the company acknowledges the challenges posed by rapid changes in pharmaceutical demand [6][7]. - The company emphasizes a cautious approach to future expansions, preferring to focus on solidifying its core product quality and maintaining a stable market position rather than pursuing aggressive acquisitions [6][7].

Group 1 - The core point of the article highlights the trading activity of Haofan Bio, which saw a closing price increase of 1.65% to 51.12 yuan on October 20 [1] - A significant block trade occurred, with a total volume of 148,100 shares and a transaction value of 6.8659 million yuan, indicating a premium rate of -9.31% [1] - The buyer was Yin Tai Securities, while the seller was Dongfang Securities, reflecting the dynamics of institutional trading in the stock [1] Group 2 - Over the past three months, Haofan Bio has recorded only one block trade, with a total transaction value of 6.8659 million yuan [1] - In the last five trading days, the stock has seen a cumulative increase of 0.24%, but there has been a net outflow of 5.3244 million yuan in principal funds [1]

Group 1 - The core transaction involved Haofan Bio, with a total of 148,100 shares traded, amounting to 6.8659 million yuan, which accounted for 16.32% of the total trading volume on that day [1] - The transaction price was 46.36 yuan per share, representing a discount of 9.31% compared to the market closing price of 51.12 yuan [1] Group 2 - The transaction occurred on October 20, 2025, under the stock code 301393 for Wufan Bio [2] - The buyer was Yintai Securities, while the seller was Dongfang Securities, with the transaction taking place at the Yanzhong Road Securities Office in Shanghai [2]